Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota
PeerJ · 03.06.2025 · 13 · e19506
DOI: 10.7717/peerj.19506 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PeerJ, online erschienen am 03.06.2025. Verfasst von Imanuely Borchardt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nutrition Josué de Castro of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Eicosapentaenoic Acid, Epigenesis, Genetic, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro, National Council for Scientific and Technological Development, Instituto Oncoclínicas.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Lung cancer is strongly associated with malnutrition and detrimental changes in muscle mass (MM), which can lead to reduced quality of life and reduced tolerance to and efficacy of antineoplastic treatment. The loss of MM and myosteatosis (fat infiltration into muscle) have been linked to inflammation in cancer, and n-3 polyunsaturated fatty acids (PUFA) found in fish oil are known to modulate inflammatory response, lean mass, microbiota, and epigenetic mechanisms.
Methods
High Eicosapentaenoic acid and PROtein (HEPRO) is a randomized, double-blind, placebo-controlled clinical trial. A total of 50 patients over 20 years of age diagnosed with stage III or IV non-small cell lung cancer with an ECOG performance status of 0–2 who are eligible for systemic treatment will be included and randomized 1:1 into two treatment arms: four fish oil capsules containing 2,100 mg EPA and 924 mg DHA per day versus four placebo capsules containing 2,250 mg oleic acid per day for 4 months. All patients will be instructed to consume 1.5 g protein per kg body weight per day and receive protein supplementation if necessary. MM, myosteatosis, muscle function, handgrip strength, dietary assessment, toxicity, response to treatment, and survival will be assessed. Translational research includes membrane phospholipid composition, gut microbiota, inflammation, and miRNA. MicroRNA will be analyzed by quantitative real-time polymerase chain reaction, phospholipids, by gas chromatography, and microbiota, by 16S ribosomal RNA genetic sequencing. Statistical analysis will be conducted using IBM SPSS Statistics V.26 and a multiple regression model will be proposed. Associations with p < 0.05 will be considered significant.
Conclusions
The HEPRO study aims to evaluate a viable dietary intervention strategy to improve MM and function in patients with lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nutrition Josué de Castro of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Oncoclínicas & Co-Medica Scientia Innovation Research, São Paulo, São Paulo, Brazil.
- Human Nutrition Research Unit, Department of Agricultural, Food & Nutritional Sciences, University of Alberta, Edmonton, Alberta, Canada.
- Laboratory of Epigenetics of Lipid Metabolism, Madrid Institute for Advanced Studies (IMDEA), Madrid University, Madri, Spain.
- Clinicobiome, Gustave Roussy Cancer Campus, Villejuif Cedex, France.
Förderung
- Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro
- National Council for Scientific and Technological Development
- Instituto Oncoclínicas
Zitieren
APA
Borchardt, I., Prado, C., Montella, T., Moreira, G. F., Farias, G., Reis, M. X., Taveira, F., Dias, F. C., De Marchi, P., Davalos, A., Silva, C. A. C., Ferreira, C. G., Melo, A., & Peres, W. (2025). Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota. PeerJ, 13, e19506. https://doi.org/10.7717/peerj.19506
Vancouver
Borchardt I, Prado C, Montella T, Moreira GF, Farias G, Reis MX, et al. Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota. PeerJ. 2025;13:e19506. doi:10.7717/peerj.19506
BibTeX
@article{Borchardt2025,
author = {Borchardt, Imanuely and Prado, Carla and Montella, Tatiane and Moreira, Gisele Fraga and Farias, Gisele and Reis, Marina Xavier and Taveira, Fernanda and Dias, Fernanda Carneiro and De Marchi, Pedro and Davalos, Alberto and Silva, Carolina Alves Costa and Ferreira, Carlos GilMoreira and Melo, Andreia and Peres, Wilza},
title = {Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota},
journal = {PeerJ},
year = {2025},
volume = {13},
pages = {e19506},
doi = {10.7717/peerj.19506}
}
EUVIMED